These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 606422)

  • 1. Histopathology of renal osteodystrophy with particular reference to the effects of 1alpha-hydroxyvitamin D3 in patients treated by long-term haemodialysis.
    Ellis HA; Pierides AM; Feest TG; Ward MK; Kerr DN
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():31s-38s. PubMed ID: 606422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease.
    Pierides AM; Ellis HA; Simpson W; Cook D; Kerr DN
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():109s-116s. PubMed ID: 606409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors influencing the response to 1alpha-hydroxyvitamin D3 in patients with renal bone disease.
    Kanis JA; Russell RG; Naik RB; Earnshaw M; Smith R; Heynen G; Woods CG
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():51s-57s. PubMed ID: 606425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variable response to long-term 1alpha-hydroxycholecalciferol in haemodialysis osteodystrophy.
    Pierides AM; Ellis HA; Simpson W; Dewar JH; Ward MK; Kerr DN
    Lancet; 1976 May; 1(7969):1092-5. PubMed ID: 57505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azotaemic renal osteodystrophy: a quantitative study on iliac bone.
    Ellis HA; Peart KM
    J Clin Pathol; 1973 Feb; 26(2):83-101. PubMed ID: 4696838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iliac bone marrow mast cells in relation to the renal osteodystrophy of patients treated by haemodialysis.
    Ellis HA; Peart KM
    J Clin Pathol; 1976 Jun; 29(6):502-16. PubMed ID: 939806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteomalacia in patients with chronic renal failure before dialysis or transplantation.
    Mora Palma FJ; Ellis HA; Cook DB; Dewar JH; Ward MK; Wilkinson R; Kerr DN
    Q J Med; 1983; 52(207):332-48. PubMed ID: 6647748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with 1,25-dihydroxycholecalciferol therapy in undergoing hemodialysis patients with progressive vitamin D2-treated osteodystrophy.
    Prior JC; Cameron EC; Ballon HS; Lirenman DS; Moriarty MV; Price JD
    Am J Med; 1979 Oct; 67(4):583-9. PubMed ID: 386792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of small doses of 1,25-dihydroxycholecalciferol in renal osteodystrophy.
    Ahmed KY; Varghese Z; Wills MR; Meinhard EA; Moorhead JF
    Lancet; 1978 Mar; 1(8065):629-32. PubMed ID: 76168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of renal bone disease.
    Lancet; 1979 Dec 22-29; 2(8156-8157):1339-40. PubMed ID: 92678
    [No Abstract]   [Full Text] [Related]  

  • 12. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.
    Andress DL; Norris KC; Coburn JW; Slatopolsky EA; Sherrard DJ
    N Engl J Med; 1989 Aug; 321(5):274-9. PubMed ID: 2631697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3.
    Voigts AL; Felsenfeld AJ; Llach F
    Arch Intern Med; 1983 Jun; 143(6):1205-11. PubMed ID: 6344827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Periosteal new bone formation (periosteal neostosis) in renal osteodystrophy. Relationship to osteosclerosis, osteitis fibrosa, and osteoid excess.
    Meema HE; Oreopoulos DG; Rabinovich S; Husdan H; Rapoport A
    Radiology; 1974 Mar; 110(3):513-22. PubMed ID: 4204516
    [No Abstract]   [Full Text] [Related]  

  • 15. The use of high calcium dialysate in the treatment of renal osteomalacia.
    Evans RA; Somerville PJ
    Aust N Z J Med; 1976 Feb; 6(1):10-5. PubMed ID: 1065293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum alkaline phosphatase in azotemic and hemodialysis osteodystrophy: a study of isoenzyme patterns, their correlation with bone histology, and their changes in response to treatment with 1alphaOHD3 and 1,25(OH)2D3.
    Pierides AM; Skillen AW; Ellis HA
    J Lab Clin Med; 1979 Jun; 93(6):899-909. PubMed ID: 438610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 25-hydroxycholecalciferol in the treatment of renal osteodystrophy in haemodialysed patients.
    Coen G; Taccone-Gallucci M; Bonucci E; Bianchini G; Gallucci G; Lucentini G; Matteucci MC; Picca S; Casciani CU
    Int J Artif Organs; 1979 Nov; 2(6):278-81. PubMed ID: 511368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Histomorphometric study of bone tissue in chronic renal failure].
    Kontek M
    Pol Arch Med Wewn; 1980 Apr; 63(4):363-73. PubMed ID: 7413466
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of 1,25(OH)2-vitamin D3 to separate 'types' on renal osteodystrophy.
    Coburn JW; Brickman AS; Sherrard DJ; Singer FR; Wong EG; Baylink DJ; Norman AW
    Proc Eur Dial Transplant Assoc; 1977; 14():442-50. PubMed ID: 600961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical spectrum of renal osteodystrophy in 57 chronic hemodialysis patients: a correlation between biochemical parameters and bone pathology findings.
    Chazan JA; Libbey NP; London MR; Pono L; Abuelo JG
    Clin Nephrol; 1991 Feb; 35(2):78-85. PubMed ID: 2019018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.